A Study of MGC028 in Participants With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

124 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-13

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally advanced of metastatic solid tumors known to express ADAM9.

The main question the study aims to answer is:

* What types of side effects will participants experience when receiving MGC028?
* Can MGC028 cause cancer to shrink, remain stable, or able to control disease progression of participants with advanced solid tumors?

Participants will

* Undergo screening procedures to determine eligibility
* Receive study treatments initially every 3 weeks.
* Have blood samples taken for routine and research tests
* Have other examinations to check heart and lung function, and general health status
* Be asked about any side effects that may be happening or other medications you are taking. The study doctor will provide treatment for side effects, if necessary.
* Have the study doctor assess your tumor status at regular intervals to determine how you are responding to treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

Advanced Solid Tumor Advanced Cancer Metastatic Cancer +19 more

RECRUITING PHASE1

A Study of AMG 820 in Subjects With Advanced Solid Tumors

NCT01444404

Advanced Malignancy Advanced Solid Tumors Cancer +3 more

COMPLETED PHASE1

A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

NCT00813384

Cancer Oncology Tumors +3 more

COMPLETED PHASE1

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

NCT06573294

Advanced Malignant Solid Tumors Metastatic Malignant Solid Tumors

RECRUITING PHASE1

Safety Study of AMG 228 to Treat Solid Tumors

NCT02437916

Advanced Malignancy Advanced Solid Tumors Cancer +8 more

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Solid Tumors NSCLC Adenocarcinoma Cholangiocarcinoma Pancreatic Carcinoma Colorectal Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type BIOLOGICAL

MGC028 is an antibody-drug conjugate targeted against ADAM9.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MGC028

MGC028 is an antibody-drug conjugate targeted against ADAM9.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants in dose escalation or supplemental cohorts must have histologically proven unresectable, locally advanced or metastatic solid tumor limited to one of the following types: NSCLC adenocarcinoma, cholangiocarcinoma, colorectal carcinoma (CRC), or pancreatic carcinoma that is refractory to standard therapy, or for which standard therapy does not exist, has proven to be intolerable, or has been refused by the participant.
* Participants in expansion cohorts must have either

* NSCLC adenocarcinoma with

* progression on or following anti-PD-1/PD-L1 inhibitor, unless contraindicated
* progression on or following therapy for actionable mutations (e.g. EGFR or ALK mutations), if present
* no more than 2 prior lines of cytotoxic chemotherapy for advanced or metastatic disease.
* Pancreatic cancer

* following at least 1 systemic therapy
* no more than 2 prior lines of cytotoxic therapy for advanced or metastatic disease.
* Colorectal adenocarcinoma with

* Progression during or following standard therapy with a fluoropyrimidine-based chemotherapy, oxaliplatin and irinotecan unless contraindicated, refused or unavailable
* Progression after prior targeted treatment for CRC with actionable mutations such as EGFR, KRAS, BRAF and MSI- H/dMMR, if present.
* No more that 2 lines of cytotoxic chemotherapy for advanced or metastatic disease
* No more than 4 lines of systemic regimens for advanced or metastatic disease
* Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1.
* Participants must have an available archival or formalin-fixed paraffin-embedded tumor tissue or be willing to undergo a biopsy procedure to obtain a fresh tumor sample.
* Participants have acceptable physical condition and laboratory values.
* Participants of childbearing potential must agree to use highly effective methods of birth control.
* Participants must not be pregnant, planning to be pregnant, or breastfeeding.

Exclusion Criteria

* Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
* Active brain metastases or leptomeningeal metastases.
* Prior stem cell, tissue, or solid organ transplant.
* Another malignancy that required treatment within the past 2 years, with the exception of those with a negligible risk of metastasis or death such as adequately treated non-melanomatous skin cancer, localized prostate cancer (Gleason Score \< 6), or carcinoma in situ.
* Active viral, bacterial, or fungal infection
* Prior treatment with ADAM9 targeted agent for cancer.
* Prior treatment with major surgery, mediastinal or lung radiation, vaccination with live virus vaccines, systemic cancer treatment, chimeric antigen receptor (CAR)-T cell therapy, or experimental treatment within 4 weeks of the start of study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No